[{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"London Health Sciences Centre","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2014","type":"Inapplicable","leadProduct":"Zinc","moa":"B1 bradykinin receptor; Methylated-DNA--protein-cysteine methyltransferase; Fructose-bisphosphate aldolase A; Elongation factor 1-alpha 1; Alpha-enolase; Glyceraldehyde-3-phosphate dehydrogenase, testis-specific; Nucleoside diphosphate kinase A; Protein disulfide-isomerase; Protein disulfide-isomerase A3; Peroxiredoxin-1; Phosphoserine phosphatase; Triosephosphate isomerase; Elongation factor Tu, mitochondrial; Estrogen receptor; Interleukin-3; Metallothionein-2; Copper chaperone for superoxide dismutase; Histone deacetylase 1; Histone deacetylase 4; DNA-3-methyladenine glycosylase; Semenogelin-1; Superoxide dismutase [Cu-Zn]; Histone deacetylase 8; Apoptosis regulatory protein Siva; Glycine receptor subunit alpha-1; E3 ubiquitin-protein ligase Mdm2; Insulin; Utrophin; Aspartoacylase; Protein S100-A8; Protein S100-A9; Matrix metalloproteinase-9; Tumor protein p73; Protein S100-A2; Cellular tumor antigen p53; Metallothionein-3; Programmed cell death protein 6; DAN domain family member 5","graph1":"Nephrology","graph2":"Phase III","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamilton Health Sciences \/ London Health Sciences Centre","highestDevelopmentStatusID":"10","companyTruncated":"Hamilton Health Sciences \/ London Health Sciences Centre"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Furosemide","moa":"Sodium-(potassium)-chloride cotransporter 2","graph1":"Nephrology","graph2":"Phase III","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamilton Health Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hamilton Health Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"Population Health Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Desmopressin Acetate","moa":"Vasopressin receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Hamilton Health Sciences \/ Population Health Research Institute","highestDevelopmentStatusID":"10","companyTruncated":"Hamilton Health Sciences \/ Population Health Research Institute"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Desmopressin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Renal Insufficiency, Chronic.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 29, 2024

                          Lead Product(s) : Desmopressin Acetate

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Population Health Research Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Voclosporin is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lupus Nephritis.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          July 27, 2023

                          Lead Product(s) : Voclosporin

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Labcorp

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Voclosporin is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lupus Nephritis.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          March 21, 2022

                          Lead Product(s) : Voclosporin

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Integrated analysis confirms addition of voclosporin to standard-of-care resulted in faster Renal Response compared to standard-of-care alone in lupus nephritis.

                          Product Name : Lupkynis

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          November 09, 2020

                          Lead Product(s) : Voclosporin,Mycophenolate Mofetil,Undisclosed

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Otsuka Pharmaceutical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Integrated analysis confirms statistically superior efficacy and safety of voclosporin in combination with MMF and steroids over standard-of-care.

                          Product Name : Lupkynis

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          October 22, 2020

                          Lead Product(s) : Voclosporin,Mycophenolate Mofetil,Undisclosed

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Otsuka Pharmaceutical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : The Company intends to use the net proceeds of the Offering for pre-commercialization and launch activities, research and development, as well as working capital and general corporate purposes.

                          Product Name : Lupkynis

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Undisclosed

                          July 27, 2020

                          Lead Product(s) : Voclosporin,Mycophenolate Mofetil,Undisclosed

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Jefferies

                          Deal Size : $200.0 million

                          Deal Type : Public Offering

                          blank

                          07

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : The FDA grants priority review designation to the evaluation of drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment for serious conditions.

                          Product Name : Lupkynis

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          July 22, 2020

                          Lead Product(s) : Voclosporin,Mycophenolate Mofetil,Undisclosed

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Otsuka Pharmaceutical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : The data showed that pre-specified confirmed estimated glomerular filtration rate (eGFR) decreases of over 30% were similar in both AURORA trial patient groups, with 10.1% reported in the voclosporin group and 10.2% in the control arm.

                          Product Name : Lupkynis

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          June 09, 2020

                          Lead Product(s) : Voclosporin

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Otsuka Pharmaceutical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : The presented data demonstrated clinically meaningful benefits of voclosporin for trial participants across ethnicities and self-reported race.

                          Product Name : Lupkynis

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          June 05, 2020

                          Lead Product(s) : Voclosporin

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Otsuka Pharmaceutical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Clinical data from its AURORA Phase 3 trial will be highlighted in a late-breaking oral presentation during the National Kidney Foundation 2020 Spring Clinical Meetings.

                          Product Name : Lupkynis

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          March 18, 2020

                          Lead Product(s) : Voclosporin,Mycophenolate Mofetil,Undisclosed

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Otsuka Pharmaceutical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank